Alzheimer's Prevention Study in Genetically Defined High-Risk Patients Includes Roche, Lilly Drugs
October 10, 2012
Alzheimer's Prevention Study in Genetically Defined High-Risk Patients Includes Roche, Lilly Drugs
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genentech Takes Personalized Medicine Approach in Pursuing Amyloid Hypothesis for Alzheimer's Drug
May 23, 2012 / Pharmacogenomics Reporter - KineMed Inks Deal with Pfizer to Use Dynamic Proteomics Platform in Diabetes Drug Development
February 3, 2012 / ProteoMonitor - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Rodent Study Suggests Low-Dose Pioglitazone May Improve Cognitive Function in Alzheimer's Patients
July 25, 2012 / Pharmacogenomics Reporter